[Clinicopathological characteristics of uninvestigated dyspepsia in Spain]. / Características clinicopatológicas de la dispepsia no investigada en España.

INTRODUCTION: Most patients with uninvestigated dyspepsia are diagnosed with functional dyspepsia. Various types of Helicobacter pylori gastritis have been described, each of which is associated with a distinct natural history of the infection (i.e. a different risk of ulcer or gastric cancer). OBJECTIVE: To determine the clinical and pathological characteristics of patients with uninvestigated dyspepsia in our area and the prevalence of the distinct types of H. pylori gastritis among patients with functional dyspepsia. MATERIAL AND METHODS: Ninety-eight patients (47 men and 51 women, mean age 35.8+/-13 years) with uninvestigated dyspepsia were included in this study. All the patients completed the Dyspepsia-Related Health Scale and all patients underwent gastroscopy with biopsy and the C13-urea breath test. RESULTS: Fourteen patients had organic causes of dyspepsia and 78 had functional dyspepsia. Fifty-one patients with functional dyspepsia (65%) had H. pylori infection; of these, 27 had pangastritis, 21 had antrum-predominant gastritis, 2 had multifocal atrophic gastritis and 1 had normal gastric mucosa. Among uninfected patients, 2 had multifocal atrophic gastritis. CONCLUSIONS: The prevalence of functional dyspepsia in this series was 85%. Twenty-seven percent of patients with functional dyspepsia had a combination of H. pylori infection and antrum-predominant gastritis, the type of gastritis predisposing to duodenal ulcer. Only 5% of the patients had multifocal atrophic gastritis, which is associated with a high risk of gastric cancer.

[Value of contrast-enhanced ultrasound in the diagnosis of hepatocarcinoma in focal lesions detected in patients with liver disease]. / Valor de los contrastes ecográficos en el diagnóstico de hepatocarcinoma en lesiones ocupantes de espacio detectadas en pacientes con hepatopatía.

OBJECTIVE: To assess the value of contrast-enhanced ultrasound in the detection of arterial hypervascularity as a diagnostic criterion of hepatocellular carcinoma (HCC) in patients with focal lesions and liver disease. PATIENTS AND METHODS: This prospective study included patients with chronic liver disease and focal liver lesions on ultrasound (US) examination. SonoVue was used as contrast agent. We employed a US imaging technique with contrast-specific software operating at a low mechanical index (< 0.14) (Hitachi EUB 6500). The contrast enhancement pattern was analyzed during the arterial phase and classified as diffuse (homogeneous or heterogeneous), peripheral, adjacent parenchyma-like enhancement, and absent. The diagnostic procedure was completed by combined study with computed tomography, magnetic resonance imaging, histologic data and clinical features. RESULTS: A total of 23 nodules in 22 patients were included in the study (one patient had two different US lesions). The final diagnosis was hepatocellular carcinoma (HCC) in 12 patients, benign lesions in nine, metastases in one and cholangiocarcinoma in one. In the 10 patients with diffuse contrast enhancement, the lesion was malignant and in the eight patients with diffuse homogeneous enhancement, the lesion was a HCC. Seventy-five percent of the patients with HCC had a diffuse enhancement pattern during the arterial phase. This pattern involved malignancy with 71.4% sensitivity, 100% specificity, 100% positive predictive value, 69.2% negative predictive value, and 82.6% accuracy. The diffuse homogeneous pattern involved HCC with 66.7% sensitivity, 100% specificity, 100% positive predictive value, 73.3% negative predictive value and 82.6% accuracy. CONCLUSIONS: Contrast-enhanced US with SonoVue allows the vascularity of focal liver lesions to be assessed. In our study, 75% of patients with HCC showed arterial hypervascularity. A diffuse homogeneous enhancement pattern during the arterial phase was highly specific to HCC. In cirrhotic patients, this arterial pattern could avoid the need for further investigations, although clinical staging should be completed with another diagnostic test.